CAS: 1402709-93-6
| Marca | Datos del producto | Pureza | Rango de precios | Entrega estimada |
|---|---|---|---|---|
 | CCT241736 REF: IN-DA01ENWXCAS: 1402709-93-6 | 98% | 180,00 €~485,00 € | Mar 10 Dic 24 |
 | CCT241736 REF: TM-T4428CAS: 1402709-93-6 | 96.2% - 99.88% | 59,00 €~482,00 € | Vie 13 Dic 24 |
 | CCT241736 REF: 3D-CGC70993CAS: 1402709-93-6 | Min. 95% | A consultar | Vie 17 Ene 25 |
Ref: IN-DA01ENWX
| 50mg | 180,00 € | ||
| 100mg | 304,00 € |
Entrega estimada en Estados Unidos, el Martes 10 de Diciembre de 2024
CCT241736
CAS:1402709-93-6
CCT241736 is an orally bioavailable dual FLT3/Aurora kinase inhibitor that also inhibits clinically relevant FLT3-resistant …
Fórmula:
C22H23Cl2N7
Pureza:
96.2% - 99.88%
Forma y color:
Solid
Peso molecular:
456.37
Ref: TM-T4428
| 5mg | 59,00 € | ||
| 10mg | 96,00 € | ||
| 25mg | 167,00 € | ||
| 50mg | 323,00 € | ||
| 100mg | 482,00 € | ||
| 1mL*10mM (DMSO) | 67,00 € |
Entrega estimada en Estados Unidos, el Viernes 13 de Diciembre de 2024
CCT241736
CAS:1402709-93-6
CCT241736 is an effective dose of a clinical drug that belongs to the class of …
Fórmula:
C22H23Cl2N7
Pureza:
Min. 95%
Peso molecular:
456.37 g/mol
Ref: 3D-CGC70993
| 5mg | A consultar | ||
| 10mg | A consultar | ||
| 25mg | A consultar | ||
| 50mg | A consultar | ||
| 100mg | A consultar |
Entrega estimada en Estados Unidos, el Viernes 17 de Enero de 2025
